Compare Quest Diagnostics Inc (DGX) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs D R Horton Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while D R Horton Inc trades at $134.81 (market cap $37.99B). The key difference: D R Horton Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and D R Horton Inc for 46 Days on average.
| DGX | DHI | |
|---|---|---|
Market Cap | $25.48B | $37.99B |
Volume | 941,866 | 2,974,460 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $167.78 |
52-Week Low | $173.49 | $132.53 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | $31.23B | $43.09B |
Dividend Yield | 1.49% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
D.R. Horton (DHI) trades at $134.49, down 0.91% on the day amid broader housing sector weakness. The stock shows bearish technical signals with resistance at $137 and support at $133. Fundamentally, the company maintains solid profitability with 9.15% net margin and 12.75% ROE, though revenue declined to $34.25B in 2025. Recent earnings beats and a $0.45 dividend declaration provide some positive catalysts despite macroeconomic headwinds affecting homebuilders.
DHI presents a mixed outlook with attractive valuation (P/E 12.95) and strong analyst support (47% buy ratings, $156.57 target) offset by housing market risks. Rising mortgage rates and inflation concerns create near-term pressure, but the company's consistent earnings performance and buyback capacity offer long-term value. Investors should weigh the discounted valuation against sector-specific macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
